rhC1INH: Clinical Trials

6 trials of rhC1INH, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 unknown. 3 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Completed 3
Phase 32Completed 2
Phase 11Unknown 1

Follow rhC1INH: new trials by email Literature Review of rhC1INH trials Research Report on rhC1INH

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function
rhC1INH, Saline Solution - Kidney Failure
Phase 1UnknownUniversity of Wisconsin, Madison202019-06-212020-12-14
Patient Registry to Evaluate the Real-world Safety of Ruconest®
rhC1INH - Hereditary Angioedema
CompletedPharming Technologies B.V.1522018-06-302024-04-05
A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor
Recombinant human C1 inhibitor, Placebo - Hereditary Angioedema
Phase 2CompletedPharming Technologies B.V.322014-12-012017-12-08
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
rhC1INH - Hereditary Angioedema
Phase 2CompletedPharming Technologies B.V.572012-01-172024-03-29
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
rhC1INH, Placebo (Saline) - Hereditary Angioedema
Phase 3CompletedPharming Technologies B.V.752011-01-012015-08-07
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
i.v. recombinant human C1 inhibitor - Genetic Disorders
Phase 2 / Phase 3CompletedPharming Technologies B.V.142004-04-012013-02-22

Conditions studied

Angioedemas, Hereditary (4)  ·  Angioedema (2)  ·  Delayed Graft Function (1)  ·  Genetic Diseases, Inborn (1)  ·  Renal Insufficiency (1)

Sponsors

Pharming Technologies B.V. (5)  ·  University of Wisconsin, Madison (1)

Countries

United States (5)  ·  Italy (3)  ·  North Macedonia (3)  ·  Romania (3)  ·  Canada (2)  ·  Czechia (2)  ·  Hungary (2)  ·  Israel (2)  ·  Poland (2)  ·  Serbia (2)  ·  Bulgaria (1)  ·  Germany (1)  ·  Netherlands (1)  ·  Slovakia (1)  ·  South Africa (1)

Top investigators

Anurag Relan, MD (2)  ·  Jan Nuijens, MD, PhD (1)  ·  Luis Fernandez (1)

Results publications

PMID 28754491, PMID 30993784, PMID 36326435, PMID 42159953